###begin article-title 0
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
Association of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 649 651 649 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 793 795 793 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1043 1045 1043 1045 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1093 1099 1093 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1164 1170 1164 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1191 1193 1191 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1239 1240 1239 1240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1243 1245 1243 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1346 1352 1346 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1384 1386 1384 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1411 1413 1411 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1480 1482 1480 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1605 1611 1605 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1624 1630 1624 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1784 1790 1784 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 507 513 <span type="species:ncbi:9135">Canary</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 902 907 <span type="species:ncbi:9606">human</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
###xml 1143 1151 <span type="species:ncbi:9606">patients</span>
###xml 1328 1336 <span type="species:ncbi:9606">patients</span>
CD40-CD154 interaction is an important mediator of inflammation and has been implicated in T helper type 1-mediated autoimmune diseases including rheumatoid arthritis (RA). Linkage studies have shown association of markers in the proximity of the CD154 gene. In the present work we investigated whether specific allele variants of the microsatellite in the 3' UTR of the CD154 gene might modulate the risk of RA. The study, in a case-control setting, included 189 patients and 150 healthy controls from the Canary Islands, Spain. The 24CAs allele was less represented in female patients than in controls (0.444 in controls versus 0.307 in patients, P = 0.006, odds ratio (OR) 0.556, 95% confidence interval (CI) 0.372 to 0.831) but not in males (0.414 versus 0.408), and only when homozygous (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77). We also verified that CD154 association with RA was independent of human leukocyte antigen (HLA) phenotype. A further functional study showed that after stimulation anti-CD3, CD154 mRNA was more stable in CD4+ T lymphocytes from patients with RA bearing the 24CAs allele (mRNA half-life 208 minutes) than in patients without the 24CAs allele (109 minutes, P = 0.009). However, a lower percentage of CD154+CD4+ T lymphocytes was seen in freshly isolated peripheral blood mononuclear cells from patients carrying 24CAs alleles (mean 4.28 versus 8.12; P = 0.033), and also in CD4+ T lymphocytes stimulated with anti-CD3 (median 29.40 versus 47.60; P = 0.025). These results were concordant with the smaller amounts of CD154 mRNA isolated from stimulated T lymphocytes with 24CAs alleles. The CD154 microsatellite therefore seems to affect the expression of the gene in a complex manner that implies not only mRNA stability. These data suggest that the CD154 microsatellite contributes to the regulation of mRNA and protein expression, although further studies will be necessary to elucidate its role in disease predisposition.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Rheumatoid arthritis (RA) is a chronic relapsing inflammatory condition of unknown etiology [1]. The disease is characterized by persistent inflammatory synovitis leading to joint destruction and is sometimes associated with systemic involvement [2]. Clinical expression of the disease ranges from a mild, non-deforming arthropathy with little long-term disability, to severe, incapacitating, deforming arthritis, which may be refractory to conventional disease-modifying agents [3]. Because early prescription of a disease-modifying anti-rheumatic drug may be more effective in controlling severe disease, early diagnosis and prediction of severity are important [4,5]. The identification of markers associated with susceptibility to or severity of RA is therefore currently an important task.
###end p 4
###begin p 5
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 483 484 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 819 820 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 366 371 <span type="species:ncbi:9606">human</span>
Twin and family studies provide evidence to support the involvement of both genetic and environmental factors in the etiopathogenesis of RA [6,7]. Epidemiological studies show an important genetic background in RA, with the major histocompatibility complex (MHC) region showing the strongest association with disease predisposition, although the contribution of the human leukocyte antigen (HLA) genes has been estimated to be no more than 30 to 50% to the total genetic background [8]. Thus, several other genes outside the MHC locus are likely to be involved, probably each contributing a small amount to the genetic predisposition to RA [7]. Recent findings from linkage studies have drawn attention to several regions that probably contain candidate genes, namely 1p, 5q, 8p, 12, 13, 18q, 21q and the X chromosome [9-15], for which association studies are needed.
###end p 5
###begin p 6
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 651 653 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 846 848 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 951 953 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 967 969 963 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1038 1040 1034 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1041 1043 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 982 990 <span type="species:ncbi:9606">patients</span>
It is believed that the pathology and etiology of RA involve abnormal presentation of self antigen(s) by antigen-presenting cells (APCs) and the activation of autoreactive T cells [16]. Several costimulatory molecules are involved during interactions between APCs and T cells, namely CD40 and CD40 ligand (CD154), which are required for the amplification of the inflammatory response [16]. In RA, T cells expressing CD40 ligand infiltrate the synovial fluid and interact with fibroblasts expressing CD40, which induces fibroblast proliferation [17], increased recruitment of inflammatory cells [18], and the production of tumor necrosis factor-alpha [19]. In addition, the production of IL-12 by synovial fluid macrophages, which is required for the initiation of T helper type 1 (Th1) cell responses, is regulated by the CD40-CD154 interaction [20]. Because RA is mediated by Th1 cells, CD40-CD154 interaction may be an important pathogenic pathway [21]. Indeed, CD4+ T cells from patients with RA have an increased expression of CD154 [21-24] that is still observed 5 to 12 years after disease onset, indicating augmented and prolonged activation of T cells.
###end p 6
###begin p 7
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 678 680 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 760 762 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 871 873 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1034 1040 1026 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1094 1100 1086 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1376 1378 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1379 1381 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1596 1602 1588 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1633 1635 1625 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
The CD154 gene is located on the X chromosome and belongs to the tumor necrosis factor gene family [25]. It contains a dinucleotide repeat of cytosine-adenine (CA) in the 3' UTR that because of its location may have some bearing on the regulation of gene expression. Although CD154 is regulated both temporally and with respect to the cell type, the underlying mechanisms responsible for this control have not yet been completely elucidated. CD154 gene transcription is induced by TCR signaling and expression is enhanced in response to costimulatory signals. Transcriptional regulation seems to be dependent on NF-AT and NF-kappaB binding sites located in the promoter region [26]. Binding sites for AP-1 and a CD28 response element have also been described [27], and a NF-kappaB binding site with enhancer activity has been found downstream of the poly(A) signal site [28]. In addition to transcriptional regulation, it has been shown that post-transcriptional regulation also has a crucial role in modulating the expression of the CD154 gene. As with other cytokine genes, the 3' UTR of the CD154 mRNA contains binding sites for RNA-protein complexes that are responsible for the lability of the mRNA. It has been found that the mRNA decay rate can be specifically modified in some situations, and the protein complexes involved in this regulation are being characterized [29-31]. It has been proposed that a putative stability complex binds specifically to a highly pyrimidine-rich region in the 3' UTR, and this complex seems to be directly involved in regulating the variable decay rate of CD154 mRNA during T cell activation [32].
###end p 7
###begin p 8
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 511 517 <span type="species:ncbi:9135">Canary</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
Allele distribution for the dinucleotide-repeat polymorphism located in the 3' UTR of the CD154 gene has previously been investigated [33,34]. Allele variants of this polymorphism have been found to be associated with RA in a subgroup of German patients [33] and with systemic lupus erythematosus in Spaniards [35] but not with multiple sclerosis in Nordic patients [36]. The aim of the present work was to study whether specific allele variants of this gene might modulate the risk of RA in Spaniards from the Canary Islands. We also investigated the influence of the allele variants of CD154 on mRNA and protein expression in peripheral-blood T cells from patients with RA.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 10
###begin p 11
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 264 270 <span type="species:ncbi:9135">Canary</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 838 850 <span type="species:ncbi:9606">participants</span>
The study used a case-control design to compare patients and controls. A total of 189 patients diagnosed with RA according to the American College of Rheumatology criteria were enrolled at the Rheumatology Unit at the Dr Negrin General Hospital from Gran Canaria (Canary Islands, Spain). The median age at onset of RA was 45 years (interquartile range 27 to 63 years) and the median disease duration was 13 years (interquartile range 2 to 24); 74% of the patients with RA were female, 78% were positive for rheumatoid factor, 80% had demonstrated erosions, and 31% presented extra-articular manifestations. All had received antimalarials or disease-modifying anti-rheumatic drugs. Control subjects (150 in all; namely 70 males and 80 females) matched by age and geography and with no history of inflammatory arthritis were recruited. All participants gave their written informed consent.
###end p 11
###begin title 12
Samples
###end title 12
###begin p 13
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Peripheral blood was obtained from patients and controls, and genomic DNA was extracted by digestion with proteinase K and extraction with phenol/chloroform [37] (Sigma-Aldrich, St Louis, MO, USA). Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation with Lymphocytes Isolation Solution (Comercial Rafer SL, Zaragoza, Spain).
###end p 13
###begin title 14
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
CD154 microsatellite typing
###end title 14
###begin p 15
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 274 278 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
A segment of the 3' UTR of the CD154 gene containing the microsatellite was amplified by PCR, and the amplification products were resolved over denaturing polyacrylamide gels as described previously [34]. Allele assignment was performed by densitometry with the Quantity One(R) Software (Bio-Rad Laboratories, Hercules, CA, USA). The length of the amplified fragment was estimated by reference to the standards used as internal ladder, and the number of repeats was calculated from the published sequence (GenBank accession number ). In 10 samples genotype assignments were confirmed with an ABIPRISM 3730 system (Applied Biosystems, Foster City, CA, USA).
###end p 15
###begin title 16
HLA typing
###end title 16
###begin p 17
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
HLA class II (DRB1 and DQB1) alleles were studied by PCR and sequence-specific oligonucleotides hybridization (PCR-SSO) using LIFEMATCHtrade mark HLA-SSO DNA Typing kits (Orchid Diagnostics, Stamford, CT, USA), in accordance with the manufacturer's instructions.
###end p 17
###begin title 18
Cell cultures
###end title 18
###begin p 19
###xml 55 57 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 307 316 300 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 344 346 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 608 611 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 709 711 699 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 133 139 <span type="species:ncbi:9913">bovine</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
PBMCs were cultured at 37degreesC in a humidified 5% CO2 atmosphere in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 mug/ml streptomycin and 2 mM L-glutamine (all from Gibco, Life Technologies Inc., Rockville, MD, USA). T lymphocytes were expanded in vitro by culturing PBMCs at 2 x 105 cells/ml in six-well culture plates (Costar, Cambridge, MA, USA) with 5 mug/ml phytohemagglutinin (PHA; Difco Laboratories, Detroit, MI, USA), 62.5 ng/ml anti-CD28 soluble mAb (Kolt-2; Menarini, Badalona, Spain), and 50 units/ml recombinant human IL-2 (Proleukin(R); Chiron BV, Amsterdam, Holland). After a week, more than 95% of the cells in the culture were CD3+ resting T lymphocytes, as confirmed by flow cytometry.
###end p 19
###begin p 20
###xml 178 181 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 406 408 397 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
For stimulation of the PBMCs or expanded T cells with anti-CD3 mAb, 24-well culture plates (Costar) were coated overnight at 4degreesC with 50 mug/ml anti-CD3 mAb (Orthoclone OKT(R)3; Cilag AG Int., Zug, Switzerland) in 50 mM Tris-HCl pH 9.5. After incubation overnight, coating solutions were removed and plates were washed gently with RPMI 1640 medium to remove unbound mAb. Cells were cultured at 5 x 105 cells/ml on anti-CD3 coated plates with 62.5 ng/ml anti-CD28 soluble mAb for 6, 24, 48, 72, or 92 hours, depending on the assay.
###end p 20
###begin title 21
mRNA decay assays
###end title 21
###begin p 22
###xml 414 416 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 571 577 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1458 1461 1456 1459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">23 </sup>
###xml 1645 1647 1642 1644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1722 1724 1718 1720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1833 1834 1829 1830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1834 1837 1830 1833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2</sub>
###xml 1853 1859 1849 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 447 450 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
###xml 643 648 <span type="species:ncbi:9606">human</span>
Expanded T cells, once they were resting, were restimulated with anti-CD3 plus anti-CD28 for 6 or 24 hours as mentioned above. Then, 10 mug/ml actinomycin D (ActD; Sigma-Aldrich), a transcriptional inhibitor, was added to the culture and aliquots of cells were collected at different time points for RNA extraction. Total RNA was isolated by the guanidinium thiocyanate method by using the Trizol reagent (Gibco) [38] and transcribed to cDNA with AMV reverse transcriptase (Roche Diagnostics, Gmbh, Mannheim, Germany), in accordance with the manufacturer's instructions. CD154 mRNA was measured by using a quantitative competitive PCR kit for human CD154 (Maxim Bio, San Francisco, CA, USA), in accordance with the manufacturer's instructions. Then, 10 mul of each reaction was subjected to electrophoresis on 2% NuSieve 3:1 agarose gels (Cambrex Bio Science Rockland, Rockland, MA, USA), and revealed by staining with ethidium bromide (Sigma-Aldrich). PCR products were quantified by using the Quantity One Software with reference to the standard from the kit. In this technique, serial dilutions of known quantities of PCR competitor are added to PCR reactions containing a constant amount of target cDNA. The molar ratio of PCR and competitor remains constant during the reaction, so the initial amount of target cDNA molecules can be calculated from the known number of competitor molecules added to the reaction as [(moles of target CD154 RNA) x (6 x 1023 molecules per mole) x (dilution factor of test RNA)]/(mug of total RNA). The number of CD154 mRNA molecules, quantified as indicated above, was then corrected for the proportion of CD4+ cells in each sample and expressed as molecules per mug of total RNA in CD4+ T lymphocytes, assuming equal RNA content between T cell subtypes. For the determination of mRNA half-lives (t1/2), fractions of CD154 mRNA remaining after the addition of ActD were plotted against time after ActD addition. After exponential adjustment of curves, mRNA half-lives were calculated as the time in which the fraction of mRNA remaining decreased to 50% of the initial amount.
###end p 22
###begin title 23
CD154 surface expression
###end title 23
###begin p 24
###xml 270 274 270 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 668 670 666 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 621 626 <span type="species:ncbi:10090">mouse</span>
Freshly isolated PBMCs or stimulated T cell suspensions were washed and stained with anti-human CD45, CD3, CD14, CD4, CD69, CD25, and CD154 mAbs (all from BD Biosciences, San Jose, CA, USA). Labeled cells were then analyzed in a FACSort flow cytometer with the CellQuest(R) software (BD Immunocytometry Systems, San Jose, CA, USA). The percentage of CD154-positive cells was calculated by subtracting overlaid CD154 and isotype control (Ig) histograms. Mean fluorescence intensity (MFI) was quantified on a linear scale as the ratio of the geometric mean of the CD154-phycoerythrin antibodies against the irrelevant anti-mouse-IgG-phycoerythrin antibodies of total CD4+ T cells.
###end p 24
###begin title 25
Apoptosis assays
###end title 25
###begin p 26
Apoptotic cells in culture were detected by staining with fluorescein isothiocyanate (FITC)-labeled annexin-V (Roche Diagnostics) and propidium iodide (Sigma-Aldrich). After 15 minutes in the dark, cells were analyzed by flow cytometry. Cell viability was measured as the percentage of cells that were negative for both annexin-V and propidium iodide.
###end p 26
###begin title 27
Proliferation assays
###end title 27
###begin p 28
PBMCs were stimulated with anti-CD3 plus anti-CD28 for three days, subsequently pulsed with 60 muM bromodeoxyuridine (BrdU) (Sigma-Aldrich), and harvested 18 hours later. The incorporation of BrdU was measured by staining with an FITC-conjugated anti-BrdU antibody (BD Biosciences) and analyzed by flow cytometry.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 357 359 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 503 508 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154</italic>
###xml 510 515 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 519 524 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1 </italic>
###xml 1048 1054 1042 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1225 1227 1219 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
Allele and genotype frequencies and carrier rates were calculated in patients with RA and in controls, and no deviations from Hardy-Weinberg equilibrium in controls were confirmed by comparison of observed and expected genotype frequencies [39]. Differences in allele/genotype frequencies between patients and healthy control subjects were tested by the chi2 method, using the Yates or Bonferroni correction or Fisher's exact test when appropriate. The strength of association between RA and alleles of CD154, DRB1 and DQB1 was estimated by using odds ratios (ORs) and the exact limits of the 95% confidence intervals (CIs). Estimation of the statistical power for the comparison of allele frequencies was performed with the STPLAN software. The arcsin approximation of the binomial distributions of allele frequencies was used with a two-sided test and with alpha fixed at 0.05. To examine interactions between variables associated with RA we conducted a multivariate analysis with a binary logistic regression model. Surface expression levels of CD154 mRNA and CD154 protein were compared by using the non-parametric Mann-Whitney test. The statistical package SSPS for Windows v. 10 (SSPS Inc., Chicago, IL, USA) was used. P < 0.05 was considered statistically significant.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
CD154 microsatellite is associated with RA in females
###end title 32
###begin p 33
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 144 146 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 152 153 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 153 155 151 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 275 281 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 307 309 305 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 368 374 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">26CAs </italic>
###xml 402 404 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 464 470 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 639 645 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 724 726 722 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 855 861 853 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">26CAs </italic>
###xml 930 932 928 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1084 1090 1082 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1127 1133 1125 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">26CAs </italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
###xml 1250 1258 <span type="species:ncbi:9606">patients</span>
Overall, allele frequencies (Additional file 1) did not differ between patients and controls after applying the Bonferroni correction to the chi2 test (pc = 0.34). However, comparison of the frequencies of each allele between patients and controls showed differences for the 24CAs allele (0.32 versus 0.44; P = 0.009; OR 0.62, 95% CI 0.44 to 0.88; power 0.70) and the 26CAs allele (0.088 versus 0.030; P = 0.014; OR 2.96, 95% CI 1.27 to 6.91; power 0.80). Because CD154 is located on the X chromosome, we compared allele frequencies between patients and controls in males and females separately. We observed statistical differences in the 24CAs allele frequency in females (0.44 in healthy controls versus 0.31 in patients; P = 0.006; OR 0.56, 95% CI 0.37 to 0.83; power 0.82) but not in males (0.41 versus 0.41). Similarly, differences were found in the 26CAs allele in females (0.03 in healthy controls versus 0.09 in patients; P = 0.033; OR 3.04, 95% CI 1.14 to 8.10; power 0.78) but not in males (0.03 versus 0.06). These data suggested a possible disease-protective role for the 24CAs variant in females. However, for the 26CAs allele, its contribution to disease predisposition does not seem to be relevant because of the low incidence in both patients and controls.
###end p 33
###begin p 34
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 121 123 121 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 415 421 415 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 491 493 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
Next, we studied genotype frequencies in females, and we found a lower frequency of the 24CAs/24CAs homozygous genotype (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77) in patients with RA than in healthy controls (Figure 1a). We then classified females as being carriers of two (24/24), one (24/X) or zero (X/X) 24CAs alleles by comparing these genotype frequencies. As can be seen in Figure 1b, RA females bearing 24CAs/24CAs were less frequent (P = 0.012), whereas X/X cases were more frequent (P = 0.042) than in healthy controls, indicating that the 24CAs allele seems to protect from RA when homozygous.
###end p 34
###begin p 35
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 105 109 105 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 209 211 209 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 295 299 295 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 523 525 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 537 539 537 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 551 553 551 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
Genotype frequencies of the CD154 microsatellite in healthy females and those with rheumatoid arthritis. (a) Seventy-nine female patients with rheumatoid arthritis (RA) were compared with 56 healthy females (Pc = 0.483). Genotypes represented fewer than five times are not included. *P = 0.012. (b) The frequency for carriers of two (24/24), one (24/X) or zero (X/X) alleles of 24CAs, where X represents any allele different from 24CAs. One hundred and forty female patients with RA were compared with 80 healthy females (Pc = 0.026). **P = 0.042, ***P = 0.012.
###end p 35
###begin title 36
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQB1</italic>
Association of CD154 with RA is independent of HLA-DRB1 and HLA-DQB1
###end title 36
###begin p 37
###xml 147 155 147 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 304 309 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1 </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 584 586 584 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">Patients</span>
###xml 417 423 <span type="species:ncbi:9135">Canary</span>
Epidemiological studies show a strong association of MHC region with disease predisposition, being related to the presence of 'shared epitopes' of HLA-DRB1, which includes the DRB1*04 and DRB1*01 alleles. To confirm whether the observed 'CD154 association' could be influenced by HLA phenotype, we typed DRB1 and DQB1 genes in our patients and controls by low-resolution PCR-SSO techniques. Patients with RA from the Canary Islands showed higher allele frequencies of DR4 (0.27 versus 0.12 in controls; P < 0.0005; OR 2.68, 95% CI 1.65 to 4.35) and DQ3 (0.39 versus 0.27 in controls; P = 0.005; OR 1.74, 95% CI 1.20 to 2.54), confirming the association of these variants with RA previously described in Spaniards [40,41].
###end p 37
###begin p 38
###xml 363 369 363 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 590 596 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 715 726 715 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154-24CAs</italic>
###xml 60 67 <span type="species:ncbi:9606">patient</span>
Next, we analyzed the distribution of pairs of variables in patient and control groups in contingency tables to test whether the association of any variable with RA depended on the presence of any other variable. This analysis revealed that the association of DQ3 with RA was dependent on DR4, as expected from the linkage of both genes (data not shown) and that CD154 was associated with RA independently of the presence of DR4 (Table 1). The influence of sex in the associated variables was analyzed by using a multivariate binary logistic regression model. The final model included DR4, 24CAs and sex as independent variables, and disease as the dependent variable. As can be seen in Table 2, the association of CD154-24CAs, but not DR4, with RA is affected by sex.
###end p 38
###begin p 39
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Distribution of 24CAs carriers among DR4+ and DR4- patients with RA and healthy controls
###end p 39
###begin p 40
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
n, number of samples analyzed. Results in parentheses are percentages.
###end p 40
###begin p 41
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
Binary logistic regression model showing influence of sex on CD154 gene association with RA
###end p 41
###begin p 42
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 42 44 42 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
OR, odds ratio; CI, confidence interval. ap value based on Wald statistic.
###end p 42
###begin title 43
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
CD154 microsatellite influences mRNA stability in T lymphocytes
###end title 43
###begin p 44
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 519 527 519 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 738 740 738 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 854 860 854 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 899 901 899 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1016 1022 1016 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1322 1328 1322 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
Because of the proximity of the CD154 microsatellite to sites regulating mRNA stability [30,32], we considered studying whether this polymorphism could affect the CD154 mRNA half-life. This gene is located on the X chromosome, so we selected homozygotic patients with RA to assign the phenotype to a single allele; these individuals were then stratified by genotype. It is known that activation of peripheral T lymphocytes in patients with RA can fluctuate, affecting to the degree of apoptosis or response to mitogens in vitro. To avoid this heterogeneity, we first used PHA, anti-CD28 and IL-2 to stimulate PBMCs from 20 patients. After 1 week in culture, homogeneous cellular populations were obtained with more than 95% of resting CD3+ lymphocytes, as confirmed by CD69 staining. The CD4/CD8 ratio of these cells did not differ between 24CAs and non-24CAs patients (2.02 and 1.82, respectively; P = 0.037). Anti-CD3 stimulation for 24 hours or more has been shown to specifically stabilize the normally unstable CD154 mRNA, augmenting its half-life notably [29]. We therefore stimulated the previously expanded T cells with anti-CD3 and anti-CD28 for 6 or 24 hours to analyze the effect of the microsatellite in both situations. After that, cells were treated with the transcriptional inhibitor ActD, and the decay of CD154 mRNA was determined by quantitative competitive reverse transcriptase-mediated PCR.
###end p 44
###begin p 45
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 124 128 124 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2 </sub>
###xml 173 179 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 211 213 205 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 230 232 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 356 362 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 367 368 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 368 372 362 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2 </sub>
###xml 441 447 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 452 453 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 453 457 445 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2 </sub>
###xml 479 481 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 498 500 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 559 565 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 684 686 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 722 728 712 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 761 767 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 853 859 843 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 956 962 946 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1016 1022 1006 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1204 1206 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
After 6 hours of stimulation, we found statistically significant differences in the half-life of CD154 mRNA between 24CAs (t1/2 49.7 +/- 17.4 minutes (mean +/- SD)) and non-24CAs alleles (32.2 +/- 10.8 minutes; P = 0.005) (Figure 2a). After 24 hours of stimulation, there was a clear mRNA stabilization in both groups of patients (fourfold increase in the 24CAs mRNA t1/2 (208 +/- 115 minutes) in comparison with a threefold increase in non-24CAs mRNA t1/2 (109 +/- 39 minutes); P = 0.009) (Figure 2a). In contrast with what we expected, the half-life of the 24CAs mRNAs was higher than that of the rest of the alleles after 6 and 24 hours of anti-CD3 stimulation. As shown in Figure 2a, scattering of the data in the non-24CAs group was similar to that in the 24CAs group. This indicated that the functional behavior of the samples included in the non-24CAs group, in spite of the inclusion of several different alleles, was as homogeneous as that in the 24CAs samples, validating our stratification of patients by 24CAs allele. A similar pattern was also observed in healthy individuals, although a statistical comparison was not performed for healthy samples because of the low sample numbers (Figure 2a).
###end p 45
###begin p 46
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 167 169 167 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 226 228 226 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 249 258 249 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 467 471 467 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 488 491 488 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2</sub>
###xml 511 515 511 515 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 557 559 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 575 577 574 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 587 589 586 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 612 618 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 637 643 636 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Expression of CD154 mRNA in T lymphocytes according to CD154 genotype. T lymphocytes from patients with rheumatoid arthritis (RA; 24CAs group, n = 9; non-24CAs group, n = 11) and controls (24CAs group, n = 3; non-24CAs group, n = 3), obtained after in vitro expansion of peripheral blood mononuclear cells, were stimulated for 6 or 24 hours with anti-CD3 plus anti-CD28; after this, mRNA decay assays were performed as indicated in the Materials and methods section. (a) mRNA half-life, t1/2, in T lymphocytes. (b) mRNA molecules per mug of total RNA in CD4+ T lymphocytes. *P < 0.05, **P < 0.005, comparing the 24CAs group with the non-24CAs group.
###end p 46
###begin p 47
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 283 289 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 360 366 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 394 396 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 512 518 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 596 601 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 603 605 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 620 622 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 787 793 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
However, if the number of molecules was compared instead of mRNA decay, the total number of CD154 mRNA molecules in CD4 T lymphocytes after 6 hours of stimulation with anti-CD3 plus anti-CD28 was significantly lower in patients with 24CAs (6.181 +/- 2.908 molecules (mean +/- SD) of CD154 mRNA per mug of total RNA in CD4 T lymphocytes) than in those with non-24CAs alleles (21.254 +/- 19.994; P < 0.05). The same occurred after 24 hours of stimulation with anti-CD3 plus anti-CD28 (3.461 +/- 2.277 molecules of CD154 mRNA per mug of total RNA in CD4 T lymphocytes, versus 7.009 +/- 8.637 in non-24CAs; P < 0.05; Figure 2b). In both cases these initial differences were shortened along the time in culture after the addition of ActD (probably as a result of the greater stability of the 24CAs mRNA).
###end p 47
###begin title 48
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
CD154 microsatellite influences surface protein expression in T lymphocytes
###end title 48
###begin p 49
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 412 414 412 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 429 431 429 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 461 462 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 465 467 465 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 545 543 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 560 562 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 644 650 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
We next tried to assess whether the CD154 microsatellite could affect protein expression in RA T lymphocytes, as we had previously described in healthy donors [35]. First, we compared the expression of several surface markers in freshly isolated PBMCs from patients with RA who were homozygous for 24CAs or non-24CAs alleles. As shown in Table 3, patients with 24CAs alleles displayed a higher percentage of CD19+ B lymphocytes (P = 0.018) and of activated CD25+CD4+ T lymphocytes (P = 0.036) but, surprisingly, a lower percentage of CD154+CD4+ T lymphocytes (P = 0.033). The MFI was also higher in patients with RA who were homozygous for non-24CAs alleles (4.44 +/- 1.02 versus 3.22 +/- 1.10), although differences did not reach statistical significance (data not shown).
###end p 49
###begin p 50
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Basal expression of surface markers in PBMCs of patients with RA according to CD154 genotype
###end p 50
###begin p 51
###xml 154 156 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 162 163 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 259 260 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 291 292 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 313 315 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Results are means +/- SD for cells expressing the indicated surface markers, quantified by flow cytometry. Differences were evaluated by the Mann-Whitney U test. n, number of samples analyzed; n.s., non significant; PBMCs, peripheral blood mononuclear cells. aReferred to total lymphocytes; breferred to total CD4+ lymphocytes.
###end p 51
###begin p 52
###xml 679 680 679 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 683 685 683 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 779 785 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 816 822 816 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 852 853 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 885 887 885 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 903 904 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1001 1007 1001 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1095 1097 1091 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
###xml 983 991 <span type="species:ncbi:9606">patients</span>
To assess the influence of the microsatellite in the kinetics of surface expression of the CD154 protein, PBMCs from both groups of homozygous patients with RA were stimulated with anti-CD3 plus anti-CD28 for 24 hours or more, to allow mRNA stabilization and thus favor protein surface expression. Initially, we verified that there were no differences between groups in the numbers of apoptotic or proliferating cells, or of contaminating monocytes (data not shown), and the activation of anti-CD3-stimulated lymphocytes was confirmed in all samples by staining for CD69 and CD25 and by flow cytometry analysis (data not shown). We observed an increase in the percentage of CD154+CD4+ lymphocytes, reaching a maximum at 48 hours in both groups, but it was lower in patients with 24CAs alleles than in those with non-24CAs alleles (median 29.4% of CD154+CD4+ lymphocytes versus 47.6%) (P = 0.025; Figure 3). Again, MFIs calculated as the ratio GeoMean CD154/GeoMean Ig were higher in patients with non-24CAs alleles but did not reach statistical significance (2.92 +/- 1.09 versus 2.37 +/- 0.83; P = 0.098).
###end p 52
###begin p 53
###xml 68 72 68 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 103 105 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 220 226 220 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 307 309 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 332 334 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 356 365 356 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 559 561 559 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 616 618 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 666 672 666 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 679 683 679 683 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 815 817 815 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 882 887 882 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 907 912 907 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
Kinetics of surface expression of CD154 in stimulated T lymphocytes (a) CD154 kinetic expression in CD4+ T lymphocytes from patients with rheumatoid arthritis (RA) after stimulation with anti-CD3/anti-CD28, according to CD154 genotype. Peripheral blood mononuclear cells from patients with RA (24CAs group, n = 19; non-24CAs group, n = 16) were stimulated in vitro with anti-CD3/anti-CD28 for 24, 48, 72, and 92 hours. After this, the surface expression of CD154 was measured by flow cytometry. The graph shows the median percentage of CD154 expression in CD4+ T lymphocytes from each group at the indicated times. *P = 0.046, comparing the 24CAs group with the non-24CAs group. (b) Cytometry histograms showing CD154 staining (thick line) compared with non-specific staining (isotype control mAb, thin line) in CD4+ T lymphocytes from representative patients with RA (upper panel, 24CAs; lower panels, non-24CAs), after 24 hours (left panels) and 48 hours (right panels) of stimulation with anti-CD3/anti-CD28. PE, phycoerythrin.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1010 1016 1010 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1189 1191 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 131 137 <span type="species:ncbi:9135">Canary</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 250 255 <span type="species:ncbi:9606">women</span>
###xml 267 270 <span type="species:ncbi:9606">men</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 824 829 <span type="species:ncbi:9606">women</span>
###xml 838 841 <span type="species:ncbi:9606">men</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
In the present study we describe the association of the microsatellite in the 3' UTR of the CD154 gene with RA in females from the Canary Islands. The 24CAs allele is less represented in patients than in controls, the difference being significant in women but not in men, and this gene variant protects from RA when homozygous. Different immunogenetic associations in male and female patients with RA have been described previously [42-46], although the mechanism underlying these differences is not fully understood. One possible explanation of these findings is that RA in males and females might be partly diverging disease entities, as proposed by Weyand and colleagues [47] or, alternatively, might result from the existence of differential hormonal influences. It is well known that RA is three times more frequent in women than in men, and many patients experience a clinical remission during pregnancy. However, it remains to be elucidated how hormonal differences might account for sex differences in CD154 association with disease susceptibility. In line with this, recent data have shown that CD154 expression could be modified by hormones such as estrogens [48] and prolactin [49].
###end p 55
###begin p 56
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR4 </italic>
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ3 </italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">21CAs </italic>
###xml 410 411 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1055 1056 1055 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1059 1061 1059 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1085 1091 1085 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">21CAs </italic>
###xml 1129 1131 1129 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1134 1136 1134 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 84 90 <span type="species:ncbi:9135">Canary</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 764 767 <span type="species:ncbi:9606">men</span>
###xml 772 777 <span type="species:ncbi:9606">women</span>
###xml 1002 1010 <span type="species:ncbi:9606">patients</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
We also demonstrate that, although HLA-DR4 and HLA-DQ3 is associated with RA in the Canary Islands population, in agreement with previous studies in Spaniards [41,44], CD154 association against RA is independent of HLA phenotype. These results differ from those previously obtained in Germans by Gomolka and colleagues [33], who described that the 21CAs allele is a risk factor for patients with RA who are DR4-DR1-. Different allele frequencies between northern and southern Europe have been described for a variety of gene polymorphisms and probably contribute to the observed discrepancy, although there are other methodological reasons that also could explain the disparity of the results. Comparisons in the German population were not performed separately in men and women, and phenotype rather allele or genotype frequencies were used. Our data arranged in that way result in a similar overall distribution of phenotype frequencies to that reported by Gomolka and colleagues in both controls and patients with RA. Similarly, in our cohort 18% of DR4-DR1- patients with RA bear a 21CAs allele, compared with only 0.5% of DR4- DR1- in controls. However, we excluded the analysis of minor alleles because the small number of individuals with those alleles did not permit reliable statistical comparisons to be made.
###end p 56
###begin p 57
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 643 649 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 846 852 846 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
We wished to see whether the association that we had found between the CD154 microsatellite and predisposition to RA was sustained by the differential expression of the gene variant associated with RA. Regulation of mRNA stability is important in controlling the expression of this gene, and the microsatellite lies close to sites of binding of protein complexes that modulate mRNA stability [29]; CA repeats have been shown to have a direct influence on mRNA stability [50], as well as on other events of gene expression [51-53]. We checked whether 24CAs alleles displayed different behaviors in relation to mRNA decay rates and compared the 24CAs mRNA with the other alleles. In agreement with previous studies [29,54], we confirmed that CD154 mRNA was more labile after 6 hours of stimulation with anti-CD3 than after 24 hours, but mRNAs with 24CAs alleles had greater half-lives than the mRNAs from the other alleles after 6 and 24 hours of stimulation with anti-CD3.
###end p 57
###begin p 58
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1027 1035 1027 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1002 1010 <span type="species:ncbi:9606">patients</span>
Regarding protein expression, non-24CAs CD4 T cells expressed more CD154 after 48 hours of stimulation with anti-CD3/anti-CD28. Because staining for CD154 produced single-peaked histograms overlapping the negative control histograms, it is difficult to provide a precise description of CD154 distribution across CD4 T cells in terms of the percentage of positive cells and the mean MFI of the positive population. Staining of a Jurkat cell line with the same antibody resulted in two peaks, with a clear separation of CD154-positive and CD154-negative subpopulations. Dilution of the anti-CD154 antibody to mimic low CD154 expression changed the shape of the histogram to form a single peak overlaid with the control peak. In this situation, the percentages of positive cells calculated by subtracting positive and negative histograms did not reflect the true fraction of positive cells and changes according to the quantity of antibody added (data not shown). Thus, the dimly stained CD4 T cells from patients with RA in our 'in vitro' assay seem to be reflecting a low density of CD154 on the surface, and the percentages of positive cells obtained probably do not reflect the true CD154-positive fraction of cells but still provide a rough measure of CD154 quantity in the CD4 T cell population.
###end p 58
###begin p 59
###xml 79 81 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 343 350 343 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 564 570 564 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 677 683 677 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 734 736 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 743 748 743 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 775 777 775 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 1130 1136 1130 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1228 1234 1228 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 1242 1247 1242 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs</italic>
###xml 544 550 <span type="species:ncbi:9606">people</span>
###xml 665 671 <span type="species:ncbi:9606">people</span>
Statistical analysis showed significant differences in the percentages of CD154+ cells but not in the MFIs. However, data on these two results look similar and both seem to provide an expression of the higher content of CD154 in non-24CAs CD4 T cells. Ultimately, what is relevant is that this differential CD154 expression may be meaningful 'in vivo', affecting the response of the immune system to autoantigens, and hence the probability of developing autoimmunity. In this regard, it is interesting that a higher CD154 protein expression in people with the non-24CAs allele has been consistently found in a variety of situations with similar differences between people with 24CAs and non-24CAs genotypes (median percentage of CD154+ cells, 24CAs/median percentage of CD154+ cells, non-24CAs: 0.64 in freshly isolated PBMCs, 0.62 in anti-CD3/anti-CD28 stimulated PBMCs, and 0.55 in PBMCs after 1 week of expansion with PHA/anti-CD28), supporting the idea that CD154 microsatellite alleles influence the expression of this gene after TCR engagement. Nevertheless, it is important to note that this higher CD154 expression in non-24CAs refers to average values, and individual percentages and MFIs substantially overlap between 24CAs and non-24CAs. We lack several replications of a single individual to estimate the variation inherent in the assay, but it is likely that a significant amount of the scattering in the data is produced by interindividual variations in several genes other than CD154 that also influence the expression of this gene after T cell activation.
###end p 59
###begin p 60
Results in protein expression seem to contrast with results on mRNA stability. However, there are some concerns about the comparison of mRNA and protein results because different sources of cells were used for each experiment. Direct comparison of these results should be taken with caution, because different proportions of T cell subsets could have distinct kinetic patterns of CD154 expression. Furthermore, times of stimulation in the analysis of mRNA and protein expression match at only one time point (24 hours), so these experiments cannot be paralleled.
###end p 60
###begin p 61
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">24CAs </italic>
###xml 698 700 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Taking the results together, the 24CAs allele, although conferring more stability on its mRNA, finally seems to result in a lower CD154 protein expression after activation. This means that the microsatellite alleles are associated not only with mRNA half-life, which seems plausible because of its location in the 3' UTR, but with other factors that probably affect the transcription of the gene and that result in a lower percentage of T cells expressing this protein on the surface after stimulation of the TCR. Although very speculative, this could be related to the NF-kappaB enhancer located near the microsatellite, which has been shown to have a crucial effect on transcription of the gene [28]. Changes in the affinity of this NF-kappaB site related to allelic variants of the microsatellite could lead to different thresholds for the activation of transcription, which in turn could lead to different percentages of cells expressing CD154 when stimulated.
###end p 61
###begin p 62
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
These results therefore seem to agree with the known pattern of CD154 expression, because it has been shown that the greatest level of CD154 expression after T cell activation occurs at a time when the mRNA is being rapidly degraded and that expression is controlled by both transcriptional mechanisms and message stability [54].
###end p 62
###begin p 63
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
More studies will be necessary to confirm the association of this microsatellite marker with RA, to establish more accurately whether the association occurs through a direct effect in the expression of the CD154 gene and, if so, what are the exact mechanisms by which different alleles lead to a different expression of the gene.
###end p 63
###begin p 64
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 105 111 <span type="species:ncbi:9135">Canary</span>
The present results and our previous data showing CD154 association with systemic lupus erythematosus in Canary Islanders suggest that CD154 may commonly contribute to the pathophysiological process and common immunogenetic mechanisms underlying both autoimmune diseases, thus being in agreement with the hypothesis of the 'common genetic origin' of autoimmune diseases [55,56].
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD154 </italic>
###xml 120 126 <span type="species:ncbi:9135">Canary</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
In the present study we report the association of the microsatellite in the 3' UTR of CD154 with RA in females from the Canary Islands. Differences found in mRNA decay according to CD154 genotypes suggest that this polymorphism may contribute to the regulation of mRNA expression, although further assays will be necessary to elucidate its role in disease predisposition. Additional studies from other series of patients will be required to confirm this genetic association.
###end p 66
###begin title 67
Abbreviations
###end title 67
###begin p 68
###xml 146 151 <span type="species:ncbi:9606">human</span>
ActD = actinomycin D; APC = antigen-presenting cell; BrdU = bromodeoxyuridine; CI = confidence interval; FITC = fluorescein isothiocyanate; HLA = human leukocyte antigen; IL = interleukin; mAb = monoclonal antibody; MFI = mean fluorescence intensity; MHC = major histocompatibility complex; NF = nuclear factor; OR = odds ratio; PBMCs = peripheral blood mononuclear cells; PCR = polymerase chain reaction; PHA = phytohemagglutinin; RA = rheumatoid arthritis; SSO = sequence-specific oligonucleotides; TCR = T-cell antigen receptor; Th = T helper type; UTR = untranslated region.
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The authors declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
###xml 402 410 <span type="species:ncbi:9606">patients</span>
TM-D and IL-F designed the study, performed the experiments, analyzed and discussed the results and prepared the manuscript. These authors contributed equally to this work, and the order of authorship is arbitrary. GP-C participated in the analysis and interpretation of the results and in manuscript preparation. IR-F, CE, and AN participated in the collection of clinical data, in the recruitment of patients and in the discussion of results. SR participated in the analysis and interpretation of the results. FS and MJC performed genotyping of the control group. AG-S participated in the collection of samples. JAV contributed to the discussion. PP-A coordinated the study, participated in its design, oversaw all aspects of the laboratory work and participated in manuscript writing and discussion. All authors read and approved the final manuscript.
###end p 72
###begin title 73
Supplementary Material
###end title 73
###begin title 74
Additional file 1
###end title 74
###begin p 75
###xml 79 87 <span type="species:ncbi:9606">patients</span>
An Excel containing data on the allelic frequencies of CD154 microsatellite in patients and controls.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 157 164 <span type="species:ncbi:558547">Gallego</span>
We are grateful to the patients with RA, the control individuals, and the collaborating clinicians for their participation in this study. We thank C. Garcia-Gallego, I. Garcia-Laorden and N. Rebolleda for their help. This study was supported by Fundacion LAIR (P1310). T.M. was supported by a grant of Comunidad de Madrid.
###end p 78
###begin article-title 79
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment
###end article-title 79
###begin article-title 80
Why does chronic inflammatory joint disease persist?
###end article-title 80
###begin article-title 81
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide
###end article-title 81
###begin article-title 82
###xml 18 23 <span type="species:ncbi:9606">human</span>
Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification
###end article-title 82
###begin article-title 83
Understanding the genetic contribution to rheumatoid arthritis
###end article-title 83
###begin article-title 84
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
###end article-title 84
###begin article-title 85
Genetic basis of rheumatoid arthritis
###end article-title 85
###begin article-title 86
Epidemiology and genetics of rheumatoid arthritis
###end article-title 86
###begin article-title 87
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study
###end article-title 87
###begin article-title 88
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases
###end article-title 88
###begin article-title 89
Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region
###end article-title 89
###begin article-title 90
Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom
###end article-title 90
###begin article-title 91
Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites
###end article-title 91
###begin article-title 92
Genome-wide meta-analysis for rheumatoid arthritis
###end article-title 92
###begin article-title 93
Genome scan meta-analysis of rheumatoid arthritis
###end article-title 93
###begin article-title 94
Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis
###end article-title 94
###begin article-title 95
The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium
###end article-title 95
###begin article-title 96
CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor
###end article-title 96
###begin article-title 97
Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes
###end article-title 97
###begin article-title 98
Regulation of CD154-induced interleukin-12 production in synovial fluid macrophages
###end article-title 98
###begin article-title 99
Functional CD40 ligand is expressed by T cells in rheumatoid arthritis
###end article-title 99
###begin article-title 100
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases
###end article-title 100
###begin article-title 101
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis
###end article-title 101
###begin article-title 102
Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment
###end article-title 102
###begin article-title 103
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily
###end article-title 103
###begin article-title 104
###xml 85 90 <span type="species:ncbi:9606">human</span>
NF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells
###end article-title 104
###begin article-title 105
The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription
###end article-title 105
###begin article-title 106
###xml 34 39 <span type="species:ncbi:9606">human</span>
A T cell-specific enhancer of the human CD40 ligand gene
###end article-title 106
###begin article-title 107
Identification of a complex that binds to the CD154 3' untranslated region: implications for a role in message stability during T cell activation
###end article-title 107
###begin article-title 108
Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression
###end article-title 108
###begin article-title 109
Nucleolin is a second component of the CD154 mRNA stability complex that regulates mRNA turnover in activated T cells
###end article-title 109
###begin article-title 110
A complex containing polypyrimidine tract-binding protein is involved in regulating the stability of CD40 ligand (CD154) mRNA
###end article-title 110
###begin article-title 111
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Immunoprinting: various genes are associated with increased risk to develop rheumatoid arthritis in different groups of adult patients
###end article-title 111
###begin article-title 112
###xml 91 97 <span type="species:ncbi:9135">Canary</span>
CD154 polymorphism in Spanish populations. Differences in the allelic distribution between Canary islanders and Peninsulars
###end article-title 112
###begin article-title 113
The dinucleotide repeat polymorphism in the 3' UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus
###end article-title 113
###begin article-title 114
Analysis of a CD40 ligand dinucleotide microsatellite in multiple sclerosis
###end article-title 114
###begin article-title 115
A general method for isolation of high molecular weight DNA from eukaryotes
###end article-title 115
###begin article-title 116
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
###end article-title 116
###begin article-title 117
Association of HLA-DR4-Dw15 (DRB1*0405) and DR10 with rheumatoid arthritis in a Spanish population
###end article-title 117
###begin article-title 118
Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain)
###end article-title 118
###begin article-title 119
###xml 79 82 <span type="species:ncbi:9606">men</span>
HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity
###end article-title 119
###begin article-title 120
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Tumor necrosis factor microsatellite haplotypes are different in male and female patients with RA
###end article-title 120
###begin article-title 121
Complex associations between HLA-DRB1 genes and female rheumatoid arthritis: results from a prospective study
###end article-title 121
###begin article-title 122
Female sex increases risk for rheumatoid arthritis only in individuals encoding low-risk HLA-DRB1 alleles
###end article-title 122
###begin article-title 123
###xml 167 175 <span type="species:ncbi:9606">patients</span>
Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients
###end article-title 123
###begin article-title 124
The influence of sex on the phenotype of rheumatoid arthritis
###end article-title 124
###begin article-title 125
###xml 58 63 <span type="species:ncbi:9606">women</span>
Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus
###end article-title 125
###begin article-title 126
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Prolactine effect on CD69 and CD154 expression by CD4+ cells from systemic lupus erythematosus patients
###end article-title 126
###begin article-title 127
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcl-2 </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcl-2 </italic>
CA repeats in the 3'-untranslated region of bcl-2 mRNA mediate constitutive decay of bcl-2 mRNA
###end article-title 127
###begin article-title 128
###xml 37 39 37 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 85 103 85 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Podospora anserina</italic>
###xml 85 103 <span type="species:ncbi:5145">Podospora anserina</span>
Modulation of gene expression by (CA)n microsatellites in the filamentous ascomycete Podospora anserina
###end article-title 128
###begin article-title 129
###xml 91 107 91 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 91 107 <span type="species:ncbi:562">Escherichia coli</span>
A downstream CA repeat sequence increases translation from leadered and unleadered mRNA in Escherichia coli
###end article-title 129
###begin article-title 130
Novel functional role of CA repeats and hnRNP L in RNA stability
###end article-title 130
###begin article-title 131
Regulation of CD154 (CD40 ligand) mRNA stability during T cell activation
###end article-title 131
###begin article-title 132
Is there a common genetic basis for autoimmune diseases?
###end article-title 132
###begin article-title 133
The common genetic hypothesis of autoimmune/inflammatory disease
###end article-title 133

